Patents by Inventor Carine Capiau
Carine Capiau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11241495Abstract: The present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.Type: GrantFiled: November 2, 2018Date of Patent: February 8, 2022Assignee: Glaxosmithkline Biologicals S.A.Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Publication number: 20200000911Abstract: The present application discloses an immunogenic composition comprising at least 2 different N. meningitidis capsular saccharides, wherein one or more is/are selected from a first group consisting of MenA, MenC, MenY and MenW which is/are conjugated through a linker to a carrier protein(s), and one or more different saccharides is/are selected from a second group consisting of MenA, MenC, MenY and MenW which is/are directly conjugated to a carrier protein(s).Type: ApplicationFiled: February 5, 2019Publication date: January 2, 2020Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Publication number: 20190298822Abstract: present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.Type: ApplicationFiled: November 2, 2018Publication date: October 3, 2019Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Patent number: 10245317Abstract: The present application discloses an immunogenic composition comprising at least 2 different N. meningitidis capsular saccharides, wherein one or more is/are selected from a first group consisting of MenA, MenC, MenY and MenW which is/are conjugated through a linker to a carrier protein(s), and one or more different saccharides is/are selected from a second group consisting of MenA, MenC, MenY and MenW which is/are directly conjugated to a carrier protein(s).Type: GrantFiled: September 14, 2016Date of Patent: April 2, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Patent number: 10166287Abstract: present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.Type: GrantFiled: August 30, 2017Date of Patent: January 1, 2019Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Patent number: 9931397Abstract: The present application relates to an immunogenic composition comprising at least 2 conjugates of N. meningitidis capsular saccharide and protein carrier, wherein said conjugates comprise at least 2 different N. meningitidis capsular saccharides selected from the group consisting of MenA, MenC, MenY and MenW, wherein at least one capsular saccharide is conjugated to a protein carrier with a saccharide:protein ratio (w/w) between 1:2-1:5, and wherein at least one different capsular saccharide is conjugated to a protein carrier with a saccharide:protein ratio (w/w) between 5:1-1:1.99.Type: GrantFiled: June 23, 2006Date of Patent: April 3, 2018Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Publication number: 20180064806Abstract: present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.Type: ApplicationFiled: August 30, 2017Publication date: March 8, 2018Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Patent number: 9789179Abstract: The present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.Type: GrantFiled: June 23, 2006Date of Patent: October 17, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Publication number: 20170065714Abstract: The present application discloses an immunogenic composition comprising at least 2 different N. meningitidis capsular saccharides, wherein one or more is/are selected from a first group consisting of MenA, MenC, MenY and MenW which is/are conjugated through a linker to a carrier protein(s), and one or more different saccharides is/are selected from a second group consisting of MenA, MenC, MenY and MenW which is/are directly conjugated to a carrier protein(s).Type: ApplicationFiled: September 14, 2016Publication date: March 9, 2017Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Patent number: 9486515Abstract: The present application discloses an immunogenic composition comprising at least 2 different N. meningitidis capsular saccharides, wherein one or more is/are selected from a first group consisting of MenA, MenC, MenY and MenW which is/are conjugated to a protein carrier(s) wherein the saccharide:protein ratio (w/w) is between 1:2-1:5, and one or more different saccharides is/are selected from a second group consisting of MenA, MenC, MenY and MenW which is/are conjugated to a protein carrier(s) wherein the saccharide:protein ratio (w/w) is between 5:1-1:1.99.Type: GrantFiled: June 23, 2006Date of Patent: November 8, 2016Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Patent number: 9358279Abstract: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 ?g.Type: GrantFiled: October 28, 2014Date of Patent: June 7, 2016Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Patent number: 9233151Abstract: A multi-valent vaccine composition is described comprising a conjugate of the capsular polysaccharide of H. influenzae b not adsorbed onto an aluminum adjuvant salt, and two or more further bacterial polysaccharides. A multi-valent vaccine composition is also described comprising a whole-cell pertussis component, tetanus toxoid, diphtheria toxoid, Hepatitis B surface antigen, a conjugate of the capsular polysaccharide of H. influenzae b, and a conjugate of a capsular polysaccharide of N. meningitidis type A or C (or both). Furthermore, a multi-valent vaccine composition is described comprising a whole-cell pertussis component, tetanus toxoid, diphtheria toxoid, and a low dose of a conjugate of the capsular polysaccharide of H. influenzae b.Type: GrantFiled: April 4, 2012Date of Patent: January 12, 2016Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Dominique Boutriau, Carine Capiau, Pierre Michel Desmons, Dominique Lemoine, Jan Poolman
-
Patent number: 9168313Abstract: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from H. influenzae.Type: GrantFiled: November 21, 2014Date of Patent: October 27, 2015Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Carine Capiau, Pierre Michel Desmons, Craig Antony Joseph Laferriere, Jan Poolman, Jean-Paul Prieels
-
Publication number: 20150079129Abstract: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from H. influenzae.Type: ApplicationFiled: November 21, 2014Publication date: March 19, 2015Inventors: Carine CAPIAU, Marguerite DESCHAMPS, Pierre Michel DESMONS, Craig Antony Joseph LAFERRIERE, Jan POOLMAN, Jean-Paul PRIEELS
-
Publication number: 20150079125Abstract: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from H. influenzae.Type: ApplicationFiled: November 21, 2014Publication date: March 19, 2015Inventors: Carine CAPIAU, Marguerite DESCHAMPS, Pierre Michel DESMONS, Craig Antony Joseph LAFERRIERE, Jan POOLMAN, Jean-Paul PRIEELS
-
Publication number: 20150044253Abstract: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 ?g.Type: ApplicationFiled: October 28, 2014Publication date: February 12, 2015Inventors: Ralph Leon BIEMANS, Dominique BOUTRIAU, Carine CAPIAU, Philippe DENOEL, Pierre DUVIVIER, Jan POOLMAN
-
Patent number: 8926985Abstract: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from H. influenzae.Type: GrantFiled: November 5, 2009Date of Patent: January 6, 2015Assignee: GlaxoSmithKline Biologicals S AInventors: Carine Capiau, Marguerite Deschamps, Pierre Michel Desmons, Craig Antonyjoseph Laferriere, Jan Poolman, Jean-Paul Prieels
-
Patent number: 8883163Abstract: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 ?g.Type: GrantFiled: February 27, 2013Date of Patent: November 11, 2014Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Publication number: 20130266609Abstract: The present invention relates to DTP-based combination vaccine formulations, and concomitantly administered combination vaccine kits. Methods of administration of these vaccines and kits are also provided.Type: ApplicationFiled: June 3, 2013Publication date: October 10, 2013Inventors: DOMINIQUE BOUTRIAU, Carine Capiau, Pierre Michel Desmons, Dominique Lemoine, Jan Poolman
-
Publication number: 20130171188Abstract: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 ?g.Type: ApplicationFiled: February 27, 2013Publication date: July 4, 2013Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Ralph Leon BIEMANS, Dominique BOUTRIAU, Carine CAPIAU, Philippe DENOEL, Pierre DUVIVIER, Jan POOLMAN